SGIOY - Viiv submits application to FDA for version of HIV treatment Triumeq for children

Viiv Healthcare, which is majority-owned by GlaxoSmithKline (GSK +0.6%),  with Pfizer (PFE -1.2%) and Shionogi (OTCPK:SGIOY -0.6%) as shareholders, has submitted an application to the FDA seeking a new formulation of its HIV pill Triumeq (abacavir/ dolutegravir/ lamivudine) in a dispersible tablet formulation. In addition, the company is asking the agency to to lower the minimum weight a child can be prescribed Triumeq from 40 kilograms (~88 pounds) to 14 kilograms (~31 pounds). According to UNAIDS, only 54% of children worldwide with HIV have access to treatment. Last week, ViiV entered into a collaboration and license agreement with Shionogi for S-365598, a third-generation investigational integrase strand transfer inhibitor for use in ultra long-acting HIV regimens.

For further details see:

Viiv submits application to FDA for version of HIV treatment Triumeq for children